Moreover, in patients with MI, ST tract elevation and with chronic HF, PTX3, but not other cardiac biomarkers, modulating complement components, predicted 3 months mortality, after adjustment for major risk factors [12, 28, 54]. This evidence concerns the gene PTX3 and myocardial infarction.